Medical treatment of pituitary adenomas;Traitement medical des adenomes hypophysaires secretants

Neurochirurgie

Volumn 44, Issue 5, 1998, Pages 309-311

  Thomopoulos, P ^a  

^a Hôpital Cochin ^*  (France)

Author keywords

Adenomas; Agonists of somatostatine; Bromocriptine somatostatine; Pituitary; Prolactinomas

Indexed keywords

BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; PROLACTIN; SOMATOSTATIN DERIVATIVE; THYROTROPIN; ANTINEOPLASTIC AGENT; HUMAN GROWTH HORMONE;

CANCER RADIOTHERAPY; DRUG HALF LIFE; DRUG INDICATION; HUMAN; HYPOPHYSIS ADENOMA; LONG TERM CARE; NEUROSURGERY; PROLACTINOMA; REVIEW; SLOW RELEASE FORMULATION; ADENOMA; HYPOPHYSIS TUMOR; MULTIMODALITY CANCER THERAPY; SECRETION;

ADENOMA; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMAN GROWTH HORMONE; HUMANS; PITUITARY NEOPLASMS; PROLACTINOMA; THYROTROPIN;

EID: 0032421677     PISSN: 00283770     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (6)

1. MOLITCH ME, THORNER MO, WILSON C. Therapeutic controversy. Management of prolactinomas. J Clin. Endocrinol Metab 1997; 82: 996-1000.
2. PELLEGRINI I, RASOLONJANAHARY R, GUNZ G, BERTRAND P, DELIVET S, JEDYNAK CP, KORDON C, PEILLON F, JAQUET P, ENJALBERT A. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989; 69: 500-509.
3. TABARIN A, CATARGI B. Traitement des macroprolactinomes par le quinagolide (Norprolac). Ann Endocrinol (Paris) 1997; 58: 87-94.
4. MORANGE I, EARLIER A, PELLEGRINI I, BRUE T, ENJALBERT A, JAQUET P. Prolactinomas resistant to bromocriptine : long-term efficacy of quinagolide and outcome of pregnancy. Eur J Endocrinol 1996 135 : 413-420.
5. COLAO A, DI SARNO A, LANDI ML, CIRILLO S, SARNAC-CHIARO F, FACCIOLLI G, PIVONELLO R, CATALDI M, MEROLA B, ANNUNZIATO L, LOMBARDI G. Long-term and low-dose treatment with cabergoline induces macro-prolactinoma shrinkace. J Clin Endocrinol Metab 1997; 82: 3574-3579.
6. COLAO A, DI SARNO A, SARNACCIIIARO F, FERONE D, DI RENZO G, MEROLA B, ANNUNZIATO L, LOMBARDI G. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997; 52: 876-883.